Opioid-Induced Constipation (OIC) Drug Market to Reach $1,463.9 Million by 2035

Opioid induced constipation (OIC) drug market was valued at $953.2 million in 2025 and is projected to reach $1,463.9 million by 2035, growing at a CAGR of 4.5% during the forecast period from 2026 to 2035. The market is being driven by the increasing clinical recognition of OIC as a significant adverse effect of opioid therapy, especially in populations with chronic pain or cancer. As prescribing of opioids persists for pain management, clinicians are more frequently identifying and documenting constipation directly linked to opioid use, which in turn increases demand for targeted therapeutic interventions. This trend has expanded the role of peripherally acting mu?opioid receptor antagonists (PAMORAs) and other OIC?specific agents in treatment protocols, creating clearer pathways for product adoption and reimbursement. Growing recognition also supports greater physician education efforts and guideline development that emphasize assessment and management of OIC symptoms as part of comprehensive opioid care. This has encouraged broader integration of OIC drugs into clinical practice, particularly in advanced healthcare systems where opioid prescribing is prevalent.

Browse the full report description of “Opioid-Induced Constipation (OIC) Drug Market Size, Share & Trends Analysis Report by Product Type (Lubiprostone, Relistor, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, and Others), and by Prescription Type (Prescribed Drug and Over-the-Counter Drug), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/opioid-Induced-constipation-oic-drug-market

Over recent years, epidemiological data show that a substantial share of patients receiving opioid therapy experience constipation, with estimates ranging from around 40?percent to 80?percent in those on chronic opioids. This wide prevalence highlights both the clinical burden of OIC and the unmet need for effective treatment options. For example, studies indicate that 40?percent–80?percent of chronic opioid users develop OIC, illustrating the scale of the patient pool driving demand for OIC therapies. In the US population, while opioid prescriptions have seen some decline, opioid use remains substantial enough to sustain OIC comorbidity, with OIC affecting roughly 1.7?percent of the general population and up to 40?percent–80?percent of long?term opioid users. This prevalence underpins ongoing growth in therapeutic adoption and supports market expansion.

Recent Developments in the Global Opioid-Induced Constipation (OIC) Drug Market

• In May 2025, Shionogi & Co., Ltd. announced that China’s regulatory authority accepted the New Drug Application for naldemedine tosilate, a treatment for opioid-induced constipation. Naldemedine, a peripherally acting ?-opioid receptor antagonist, is already marketed in Japan, the US, Europe, and Taiwan, providing targeted relief to OIC patients across multiple regions.

• In December 2024, Bausch Health and Salix Pharmaceuticals, in collaboration with USPF, IFFGD, and ACPA, declared December 5, 2024, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. The initiative seeks to raise public and clinical awareness of OIC, reduce stigma associated with the condition, and encourage open discussions to support affected patients.

• In July 2024, Grünenthal acquired US-based Valinor Pharma and its OIC product Movantik® (naloxegol) for approximately $250 million, including royalties, funded through available liquidity. Movantik® provides treatment for opioid-induced constipation in adults with chronic non-cancer pain, strengthening Grünenthal’s portfolio in gastrointestinal therapeutics.

• On June 28, 2024, Luye Pharma’s Mimeixin, a sustained-release tablet combining oxycodone and naloxone, received approval from China’s NMPA for managing severe adult pain, including cancer and non-cancer pain. The inclusion of naloxone mitigates opioid-induced constipation by blocking oxycodone’s receptors in the gastrointestinal tract.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Product Type
  • Prescription Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AstraZeneca PLC, Bausch Health Companies Inc., Pfizer Inc., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Opioid-Induced Constipation (OIC) Drug Market Report Segment

By Product Type

• Lubiprostone
• Relistor
• Methyl Naltrexone Bromide
• Naldemedine
• Alvimopan
• Others

By Prescription Type

• Prescribed Drug
• Over-the-Counter Drug

Global Opioid-Induced Constipation (OIC) Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/opioid-Induced-constipation-oic-drug-market